Prostate stem cell antigen is expressed in normal and malignant human brain tissues

Ono,Hiroe; Sakamoto,Hiromi; Yoshida,Teruhiko; Saeki,Norihisa

doi:10.3892/ol.2017.7632

Prostate stem cell antigen is expressed in normal and malignant human brain tissues

Authors:
- Hiroe Ono
- Hiromi Sakamoto
- Teruhiko Yoshida
- Norihisa Saeki
View Affiliations

Affiliations: Division of Genetics, National Cancer Center Research Institute, Tokyo 104‑0045, Japan
Published online on: December 18, 2017 https://doi.org/10.3892/ol.2017.7632
Pages: 3081-3084

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Prostate stem cell antigen (PSCA) is a glycosylphosphatidylinositol (GPI)‑anchored cell surface protein and exhibits an organ‑dependent expression pattern in cancer. PSCA is upregulated in prostate cancer and downregulated in gastric cancer. PSCA is expressed in a variety of human organs. Although certain studies previously demonstrated its expression in the mammalian and avian brain, its expression in the human brain has not been thoroughly elucidated. Additionally, it was previously reported that PSCA is weakly expressed in the astrocytes of the normal human brain but aberrantly expressed in glioma, suggesting that PSCA is a promising target of glioma therapy and prostate cancer therapy. The current study identified PSCA expression in the neural and choroid plexus cells of the normal human brain by immunohistochemistry. In brain tumors, PSCA was expressed in medulloblastoma and glioma, and its expression was also observed in papilloma and papillary carcinoma of the choroid plexus, ependymoma and meningioma. The results suggest that PSCA may have a tumor‑promoting function in brain tumors and is a potential target for their therapy. However, its expression in normal neuronal and choroid plexus cells implies that a PSCA‑targeted therapy may lead to certain adverse phenomena.

View Figures

View References

1	Saeki N, Gu J, Yoshida T and Wu X: Prostate stem cell antigen: A Jekyll and Hyde molecule? Clin Cancer Res. 16:3533–3538. 2010. View Article : Google Scholar : PubMed/NCBI
2	Sharom FJ and Radeva G: GPI-anchored protein cleavage in the regulation of transmembrane signals. Subcell Biochem. 37:285–315. 2004. View Article : Google Scholar : PubMed/NCBI
3	Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, et al: Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA. 95:pp. 1735–1740. 1998; View Article : Google Scholar : PubMed/NCBI
4	Study Group of Millennium Genome Project for Cancer, ; Sakamoto H, Yoshimura K, Saeki N, Katai H, Shimoda T, Matsuno Y, Saito D, Sugimura H, Tanioka F, et al: Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat Genet. 40:730–740. 2008. View Article : Google Scholar : PubMed/NCBI
5	Ono H, Hiraoka N, Lee YS, Woo SM, Lee WJ, Choi IJ, Saito A, Yanagihara K, Kanai Y, Ohnami S, et al: Prostate stem cell antigen, a presumable organ-dependent tumor suppressor gene, is down-regulated in gallbladder carcinogenesis. Genes Chromosomes Cancer. 51:30–41. 2012. View Article : Google Scholar : PubMed/NCBI
6	Argani P, Rosty C, Reiter RE, Wilentz RE, Murugesan SR, Leach SD, Ryu B, Skinner HG, Goggins M, Jaffee EM, et al: Discovery of new markers of cancer through serial analysis of gene expression: Prostate stem cell antigen is overexpressed in pancreatic adenocarcinoma. Cancer Res. 61:4320–4324. 2001.PubMed/NCBI
7	Kawaguchi T, Sho M, Tojo T, Yamato I, Nomi T, Hotta K, Hamada K, Suzaki Y, Sugiura S, Kushibe K, et al: Clinical significance of prostate stem cell antigen expression in non-small cell lung cancer. Jpn J Clin Oncol. 40:319–326. 2010. View Article : Google Scholar : PubMed/NCBI
8	Geiger KD, Hendruschk S, Rieber EP, Morgenroth A, Weigle B, Juratli T, Senner V, Schackert G and Temme A: The prostate stem cell antigen represents a novel glioma-associated antigen. Oncol Rep. 26:13–21. 2011.PubMed/NCBI
9	Jensen MM, Arvaniti M, Mikkelsen JD, Michalski D, Pinborg LH, Härtig W and Thomsen MS: Prostate stem cell antigen interacts with nicotinic acetylcholine receptors and is affected in Alzheimer's disease. Neurobiol Ageing. 36:1629–1638. 2015. View Article : Google Scholar
10	Hruska M, Keefe J, Wert D, Tekinay AB, Hulce JJ, Ibañez-Tallon I and Nishi R: Prostate stem cell antigen is an endogenous lynx1-like prototoxin that antagonizes alpha7-containing nicotinic receptors and prevents programmed cell death of parasympathetic neurons. J Neurosci. 29:14847–14854. 2009. View Article : Google Scholar : PubMed/NCBI
11	Thomsen MS, Cinar B, Jensen MM, Lyukmanova EN, Shulepko MA, Tsetlin V, Klein AB and Mikkelsen JD: Expression of the Ly-6 family proteins Lynx1 and Ly6H in the rat brain is compartmentalized, cell-type specific, and developmentally regulated. Brain Struct Funct. 219:1923–1934. 2014. View Article : Google Scholar : PubMed/NCBI
12	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
13	Ono H, Yanagihara K, Sakamoto H, Yoshida T and Saeki N: Prostate stem cell gene is expressed in islets of pancreas. Anat Cell Biol. 45:149–154. 2012. View Article : Google Scholar : PubMed/NCBI
14	Moore ML, Teitell MA, Kim Y, Watabe T, Reiter RE, Witte ON and Dubey P: Deletion of PSCA increases metastasis of TRAMP-induced prostate tumors without altering primary tumor formation. Prostate. 68:139–151. 2008. View Article : Google Scholar : PubMed/NCBI
15	Wente MN, Jain A, Kono E, Berberat PO, Giese T, Reber HA, Friess H, Büchler MW, Reiter RE and Hines OJ: Prostate stem cell antigen is a putative target for immunotherapy in pancreatic cancer. Pancreas. 31:119–125. 2005. View Article : Google Scholar : PubMed/NCBI
16	Morris MJ, Eisenberger MA, Pili R, Denmeade SR, Rathkopf D, Slovin SF, Farrelly J, Chudow JJ, Vincent M, Scher HI and Carducci MA: A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer. Ann Oncol. 23:2714–2719. 2012. View Article : Google Scholar : PubMed/NCBI